These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 816686)

  • 41. [Relation of the sex of guinea pigs to sensitivity to Brucella abortus infection and their immune response].
    García-Carrillo C
    Rev Asoc Argent Microbiol; 1978; 10(1):8-13. PubMed ID: 98812
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of cell-mediated immune responses and bacterial clearance in 6-10 months old water buffalo (Bubalus bubalis) experimentally vaccinated with four dosages of commercial Brucella abortus strain RB51 vaccine.
    Diptee MD; Adesiyun AA; Asgarali Z; Campbell M; Fosgate GT
    Vet Immunol Immunopathol; 2005 Jul; 106(3-4):209-20. PubMed ID: 15963819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of gamma radiation and azathioprine on Brucella abortus infection in BALB/c mice.
    Elzer PH; Rowe GE; Enright FM; Winter AJ
    Am J Vet Res; 1991 Jun; 52(6):838-44. PubMed ID: 1909103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brucella melitensis Rev. 1 and Brucella abortus 45-20 vaccines in goats: pattern of immunoglobulin production after vaccination and challenge.
    Varela-Diaz VM; Jones LM; Perez-Esandi MV
    Am J Vet Res; 1973 Feb; 34(2):203-7. PubMed ID: 4631097
    [No Abstract]   [Full Text] [Related]  

  • 45. Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection.
    Mallick AI; Singha H; Chaudhuri P; Nadeem A; Khan SA; Dar KA; Owais M
    Vaccine; 2007 May; 25(18):3692-704. PubMed ID: 17296251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reactivation of a residual Brucella abortus 19 vaccine infection in mice by a virulent challenge or by injection of brucellin or of Brucella lipopolysaccharide.
    Plommet M; Plommet AM
    Ann Rech Vet; 1988; 19(4):245-51. PubMed ID: 3148291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rough vaccines in animal brucellosis: structural and genetic basis and present status.
    Moriyón I; Grilló MJ; Monreal D; González D; Marín C; López-Goñi I; Mainar-Jaime RC; Moreno E; Blasco JM
    Vet Res; 2004; 35(1):1-38. PubMed ID: 15099501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of immunity produced by B. melitensis Rev. 1 and B. abortus strain 19 in guinea pigs challenged a month nd a year after vaccination ].
    García-Carrillo C
    Zentralbl Veterinarmed B; 1986 Apr; 33(3):231-6. PubMed ID: 3092508
    [No Abstract]   [Full Text] [Related]  

  • 49. Brucella abortus strain RB51 vaccine: its advantages and risks.
    Kahler SC
    J Am Vet Med Assoc; 1998 Jul; 213(1):12, 22. PubMed ID: 9656011
    [No Abstract]   [Full Text] [Related]  

  • 50. Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model.
    Pakzad I; Rezaee A; Rasaee MJ; Tabbaraee B; Delpisheh A
    Iran J Immunol; 2009 Mar; 6(1):12-21. PubMed ID: 19293473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunologic, histopathologic, and bacteriologic responses of five strains of mice to Brucella abortus strain 2308.
    Pugh GW; Zehr ES; Meador VP; Phillips M; McDonald TJ; Deyoe BL
    Am J Vet Res; 1989 Mar; 50(3):323-8. PubMed ID: 2494913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Immuno-stimulating effect of levamisole in the immunization of guinea pigs vaccinated against brucellosis].
    Sandoval LA; Giorgi W; Amaral LB; Zampolli E; Manzati MT
    Arq Inst Biol (Sao Paulo); 1978; 45(4):313-7. PubMed ID: 754679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenic properties of soluble antigens or whole cells of Brucella abortus strain 45/20 associated with immunoadjuvants. I. Soluble antigens.
    Woodard LF; Toone NM; McLaughlin CA
    Can J Comp Med; 1980 Oct; 44(4):453-5. PubMed ID: 6778599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Experimental evaluation of the brucellosis therapeutic vaccine efficacy].
    Shabalin BA; Okhapkina VIu; Gavrilova LB; Saiapina LV
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (2):38-43. PubMed ID: 17523477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Brucella abortus (strain 544) variants.
    Hopkins IG; Thornton DH; Hebert CN
    J Biol Stand; 1981 Oct; 9(4):421-9. PubMed ID: 6798039
    [No Abstract]   [Full Text] [Related]  

  • 56. [Treatment of experimental brucellosis of mice and guinea pigs by rifampicin].
    Philippon A; Kazmierczak A; Plommet M; Marly J; Nevot P
    Dev Biol Stand; 1976; 31():279-86. PubMed ID: 816684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancement activity of anti-brucella sera in experimental Brucella abortus infection in mice.
    Forget A; Riendeau C
    Rev Can Biol; 1977 Sep; 36(3):239-43. PubMed ID: 412235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The possibility of creating a vaccinal strain of Brucella abortus 19-BA with multiple antibiotic resistance].
    Gorelov VN; Gubina EA; Grekova NA; Skavronskaia AG
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Sep; (9):2-4. PubMed ID: 1759514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Optimal immunizing doses of vaccinal strains of Brucella].
    Shumilov KV
    Veterinariia; 1979 Aug; (8):31-4. PubMed ID: 113924
    [No Abstract]   [Full Text] [Related]  

  • 60. Antibody response, delayed hypersensitivity, and immunity in guinea pigs induced by smooth and rough strains of Brucella abortus.
    Jones LM; Berman DT
    J Infect Dis; 1971 Jul; 124(1):47-57. PubMed ID: 5004116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.